Pharmaceutical Manufacturing of Oral Contraceptives

The contract encompasses the manufactured production of oral contraceptive tablets containing levonorgestrel and ethinyl estradiol in a fixed ratio of 0.125 mg to 0.030 mg per tablet, to be packaged in 28-day cycles comprising 21 active tablets followed by 7 inert tablets, adhering strictly to USP, FDA, and Department of Defense quality and compliance standards. The finished product must meet a minimum shelf life of 21 months at the time of delivery, ensuring long-term stability and usability under standard storage conditions. Manufacturing must occur under current good manufacturing practices and include full documentation, testing, and validation to satisfy regulatory and military procurement requirements. The solicitation is issued under the Department of Defense’s Medical Supply Chain Pharm FSA, with performance located at Fort Stewart, Georgia, 31314-5185, indicating a direct logistical and supply chain integration with military medical operations. The contract is structured as a subcontract with a solicitation response deadline of August 3, 2026, and falls under NAICS code 325412 for pharmaceutical preparation manufacturing. The timing and specificity suggest a strategic procurement effort to secure reliable, long-duration contraceptive supplies for military personnel, with no set-aside provisions indicated, opening participation to qualified manufacturers without restriction based on business size or status.